Cantor Fitzgerald Europe Takes 37.02% Stake in Inspeq (6656) | Large Shareholding Report

A large shareholding report (EDINET filing) shows that CANTOR FITZGERALD EUROPE has raised its stake in Inspeq (6656) to 37.02%. This acquisition was made by the European asset management division of the Cantor Fitzgerald group. The company manufactures and sells precision inspection equipment for semiconductors (AVI/AOI) and related services as an electrical machinery manufacturer. The 37% shareholding represents a controlling stake equivalent to roughly one-third of the company's market capitalization. No filing by the same investor was detected within the previous 400 days, indicating this represents a substantial new entry or major resumption of the position.

The investor's portfolio composition reveals a pronounced concentration in retail and pharmaceutical sectors. The firm maintains shareholdings exceeding 37% in two retail companies: Vector Holdings (2656, 37.5%) and Star Seeds (3083, 36.68%), while holding multiple pharmaceutical positions including Carna Biosciences (4572, 28.34%), Anges (4563, 18.14%), and Tsubota Lab (4890, 18.63%). Inspeq, as an electrical machinery manufacturer, represents a new sector addition to this investor's portfolio. The investment approach is characterized by maintaining high single ownership stakes typically ranging from 18% to 40% across multiple holdings.

Within Inspeq's shareholder structure, CANTOR FITZGERALD EUROPE ranks as the largest shareholder at 37.02%. The second-largest holder, SilverCape Investments Limited, controls only 9.75%, while individual shareholder Masashi Sugawara holds 4.79%. The disparity underscores the overwhelming influence of the new majority shareholder over the company's overall shareholder composition.

At the time of disclosure, Inspeq's stock price stood at ¥808, with a PER of 42.2x and PBR of 3.93x. The share price positioned itself at 35% within the 52-week trading range, indicating a mid-to-lower range position. The elevated PER exceeding 40x and PBR approaching 4x reflect high valuation multiples, while the down-risk assessment at this point was classified as elevated.